GL 522 Y 1

Drug Profile

GL 522 Y 1

Alternative Names: Y 1

Latest Information Update: 03 Jun 1999

Price : $50

At a glance

  • Originator Genelabs Technologies
  • Class Antithrombotics; Vascular disorder therapies
  • Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atherosclerosis; Deep vein thrombosis; Embolism; Thrombosis; Unstable angina pectoris

Most Recent Events

  • 03 Jun 1999 A preclinical study has been added to the Thromboses pharmacodynamics section
  • 07 Mar 1996 Discontinued-Preclinical for Atherosclerosis in USA (Unknown route)
  • 07 Mar 1996 Discontinued-Preclinical for Embolism in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top